key: cord-0748508-at8j60hl
authors: Zucman, Noémie; Uhel, Fabrice; Descamps, Diane; Roux, Damien; Ricard, Jean-Damien
title: Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report
date: 2021-02-10
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab129
sha: 6d4a9522986f33d6f706ee5b674ce6f1a05dce3d
doc_id: 748508
cord_uid: at8j60hl

nan

The rapid acquisition of herd immunity appears to be the only way out of the COVID-19 pandemic.

However, the strength and duration of immunity against this coronavirus are still uncertain.

Reinfections have been described but remain rare albeit probably underestimated (31 confirmed cases worldwide as of January 2021), and in most cases less severe than the initial infection [1, 2] .

However, major concern is arising from the recent description of variants carrying mutations providing SARS-CoV-2 with selective advantages. Three emerging variants of concern (VOC) are currently associated with a new rise in the incidence and mortality related to COVID-19. There are well-grounded fears that these VOC could cause reinfections or post-vaccination infections. As a matter of fact, we read with interest the article by Harrington et al. describing a case of reinfection with SARS-CoV-2 Variant VOC-202012/01 [3] .

We here report a case of severe SARS-CoV-2 reinfection with South African variant 501Y.V2, four months after recovering from a first episode of COVID-19. In September 2020, a 58-year old immunocompetent male with a history of asthma presented with mild fever and dyspnea. SARS-CoV-2 infection was diagnosed by real-time RT-PCR on a nasopharyngeal swab. Symptoms resolved within a few days and the patient tested negative twice in December 2020. In January 2021, 129 days after onset of the first infection, he presented to hospital for recurrent dyspnea and fever. This is, to our knowledge, the first description of reinfection with the South African SARS-CoV-2 VOC 501Y.V2 causing severe COVID-19, four months after a first mild infection. Whether SARS-CoV-2 infection confers immunity against recurrent infections remains controversial. Experimental reinfections in rhesus macaques and follow-up of patients infected during the first wave suggest that adaptive immunity confers acceptable protection against reinfection for at least six months [4, 5] .

However, cases of SARS-CoV-2 reinfections despite detectable serum levels of neutralizing antibodies have been reported, some of which being more severe than the first occurrence [6] . The emergence of variants with increased virulence is a new a matter of concern. The 501Y.V2 variant, initially detected in South Africa, has rapidly spread worldwide as of December 2020 [7] . It is characterized by eight mutations in the spike protein-coding sequences, including three in the receptor-binding domain (K417N, E484K and N501Y) that may account for its increased transmissibility [8] . This variant has not been reported to be responsible for more severe disease or worse outcomes so far [9] . However, the impact of 501Y.V2 mutations on the effectiveness of vaccines developed based on earlier SARS-CoV-2 strains is still unknown.

Our case illustrates that the 501Y.V2 SARS-CoV-2 variant can also be responsible for severe reinfections after a first mild infection with non-VOC SARS-CoV-2. Further investigation is urgently needed to assess cross immunity against VOC 501Y.V2, and to monitor vaccine effectiveness against new variants. A c c e p t e d M a n u s c r i p t 5

The Importance and Challenges of Identifying SARS-CoV-2 Reinfections

Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease

Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01

What we know about covid-19 reinfection so far

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Genomic evidence for reinfection with SARS-CoV-2: a case study

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA -first update